분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-12-10 01:00:21 , Hit : 1827
 FDA approves Gilead's breakthrough hepatitis C pill


Fri Dec 6, 2013 6:34pm EST
0 Comments inShare4Share this
Email
Print

(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi, also known as sofosbuvir, as a potential cure for chronic infection with the liver-destroying hepatitis C virus.

The once-a-day pill is the first approved to treat certain types of hepatitis C infection without the need for interferon, an injected drug that can cause severe flu-like symptoms.

Hepatitis C, which is often undiagnosed, affects about 3.2 million Americans, killing more than 15,000 each year, mostly from illnesses such as cirrhosis and liver cancer.

Most patients will be treated with the $7,000-a-week drug for 12 weeks, resulting in a total price of $84,000, according to Gilead spokeswoman Cara Miller.

"Today marks a landmark advance in the treatment of hepatitis C, opening up new opportunities to stop the spread of this virus and the ravages of this disease," Dr John Ward, director of the Centers for Disease Control and Prevention's division of viral hepatitis, said in a statement.

Last year, the CDC recommended that all baby boomers, born from 1945 to 1965, be tested for the virus. Introduction of blood and organ screening in the 1990s has dramatically lowered infection rates for younger generations.

Gilead said Sovaldi can be used in combination with ribavirin, an older antiviral pill, for patients with genotypes 2 and 3 infections, which account for about 28 percent of U.S. patients infected with the virus.

For patients with genotype 1, which accounts for about 70 percent of U.S. infections, the new drug must still be used with both interferon and ribavirin, although it can be considered for use in patients with genotype 1 infections who cannot use interferon.

Patients with the much less common genotype 4 infections must also still be treated with the 3-drug combination.

The drug's approval was supported by several studies showing that it helped to eradicate the virus in significantly more patients, with fewer side effects, than the current drug regimen.

Sovaldi is the first in a new class of medications known as nucleotide analogue inhibitors, or "nukes," designed to block a specific protein that the hepatitis C virus needs to copy itself.

Analysts, on average, have forecast Sovaldi sales of $1.9 billion next year, according to BMO Capital Markets.

Shares of Gilead, which have nearly doubled over the past 12 months, were up half a percentage point at $74.39 in after-hours trading. The shares rose 1 percent to close at $73.99 in regular Nasdaq trading on Friday.

(Reporting By Deena Beasley; Editing by Leslie Adler)







827   Gene therapy 'could be used to treat blindness'Pallab Ghosh  이성욱 2014/01/23 1746
826   신비로운 RNA 변형의 핵심적 역할 조명  이성욱 2014/01/14 2263
825   줄기세포 요법 개발을 제한하는 문제점의 해결 방법  이성욱 2014/01/07 2055
824   2013년 Nature에 실린 과학뉴스 총결산  이성욱 2014/01/01 2536
823   세포자살을 막는 방법을 통한 HIV치료  이성욱 2013/12/26 2529
822   HPV Home Tests Could Identify Cancer Risk  이성욱 2013/12/25 1977
821   네이처 선정 2013년 10대 과학자  이성욱 2013/12/23 1938
820   텔로미어 연구  이성욱 2013/12/23 2757
819   인간 난자의 DNA 염기서열을 해독하는 비침습적 방법 개발  이성욱 2013/12/23 2325
818   일시적인 바이러스성 DNA 도관  이성욱 2013/12/20 1973
817   유방암 전이의 첫번째 단계를 차단하는 방법  이성욱 2013/12/20 2228
816   그림의 떡 - 한 알에 1,000달러짜리 C형간염 신약 소포스부비어  이성욱 2013/12/20 2320
815   기능 유전체학을 가속화시킬 새로운 기술  이성욱 2013/12/19 1947
814   광범위한 질병을 치료할 수 있는 새로운 약물접근법  이성욱 2013/12/13 1822
813   Hopes of HIV cure in 'Boston patients' dashed  이성욱 2013/12/11 2609
812   자폐증을 치료하는 박테리아  이성욱 2013/12/10 2011
811   유전자치료평가를 둘러싼 미국 규제당국의 역할논쟁  이성욱 2013/12/10 2030
810   악성 세포는 유전체 복제 경로가 다르다  이성욱 2013/12/10 1892
  FDA approves Gilead's breakthrough hepatitis C pill  이성욱 2013/12/10 1827
808   악성 유방암에서 종양 억제자 Rb의 새로운 기능 규명!  이성욱 2013/12/09 2425

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN